Retroviral Vector Design for Gene Therapy of Cancer: Specific Inhibition and Tagging of BCR-ABLp190 Cells

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Molecular Medicine

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF03402208PMID 8900540PMCID PMC2230033
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2.

  1995cited by this paper
• Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.

  1994cited by this paper
• Gene inhibition using antisense oligodeoxynucleotides

  1994cited by this paper
• Transcriptional activation by TAL1 and FUS-CHOP proteins expressed in acute malignancies as a result of chromosomal abnormalities.

  1994cited by this paper
• In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence

  1994cited by this paper
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

  1993cited by this paper
• Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice.

  1993cited by this paper
• LIM domain proteins in leukaemia and development.

  1993cited by this paper
• Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.

  1991cited by this paper
• Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins

  1991cited by this paper
• The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos

  1991cited by this paper
• Normal c-abl gene protein--a nuclear component.

  1991cited by this paper
• Acute leukaemia in bcr/abl transgenic mice

  1990cited by this paper
• bcr‐abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.

  1990cited by this paper
• Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

  1990cited by this paper
• Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

  1990cited by this paper
• Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells

  1989cited by this paper
• Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.

  1988cited by this paper
• The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts.

  1987cited by this paper
• Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL.

  1987cited by this paper
• Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia.

  1987cited by this paper
• Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome.

  1986cited by this paper
• Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo.

  1985cited by this paper
• Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

  1985cited by this paper
• An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

  1984cited by this paper

• Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy.

  2015cites this paper
• Cancer development induced by graded expression of Snail in mice.

  2005cites this paper
• Inhibidores de BCR-ABL como un abordaje molecular de la leucemia mieloide crónica.

  2003cites this paper
• BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia

  2002cites this paper
• Aspectos actuales y previsiones de futuro de la terapia génica

  2002cites this paper
• Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Is Initiated in an Uncommitted Progenitor Cell

  2001cites this paper
• A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia.

  2000cites this paper
• In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment.

  2000cites this paper
• Chromosomal abnormalities and tumor development: from genes to therapeutic mechanisms

  1998cites this paper
• [Nonviral methods of gene transfer in gene therapy].

  1997cites this paper
• Murine hematopoietic reconstitution after tagging and selection of retrovirally transduced bone marrow cells.

  1997cites this paper
• A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product.

  1997cites this paper
• Consequences of chromosomal abnormalities in tumor development.

  1997cites this paper
• Tyrosinkinaseinhibitoren Ein Ansatz zur Pathogeneseorientierten Tumortherapie

  1997cites this paper
• Gene therapy of cancer

  1996cites this paper